Adam Lessler

GT Medical Technologies was founded by a dedicated team of brain tumor specialists to address unmet needs in brain tumor treatment. The company is committed to improving the lives of patients with brain tumors through innovative solutions that elevate the standard of care. GammaTile is an FDA-cleared, bioabsorbable collagen implant embedded with radiation seeds, designed for patients with operable brain tumors. By delivering radiation directly from within—placed into the surgical cavity at the time of tumor removal—GammaTile provides immediate, localized treatment. This approach targets remaining cancer cells when they are at their lowest levels to help prevent regrowth, while minimizing radiation exposure to healthy brain tissue.(1) Since its full market launch in the United States in March 2020, GammaTile has been adopted by more than 100 leading centers, underscoring its growing acceptance in both academic and community healthcare settings. For more information, visit gammatile.com. Reference: 1. Garcia MA et al. J Neurooncol. 166:203-212 (2024).

PreludeDx was founded to deliver actionable tools to manage early stage breast cancer. PreludeDx's first diagnostic test, DCISionRT is the result of over a decade of research and development focused on DCIS. PreludeDx began developing its DCIS test in 2009 after licensing technology from University of California, San Francisco. DCISionRT’s technology was designed from the beginning to address the critical question faced by patients with DCIS. What is my risk of recurrence and what treatment is appropriate?

Standard Molecular’s mission is to make clinical genomic testing routine. Personalized medicine, genetic testing, and cancer genomics present unique opportunities to clinicians in terms of diagnostic and therapeutic innovation. Standard Molecular, Inc. has developed Continuity GIS™, the first purpose-engineered Genomic Information System for molecular pathology. This tool was designed for molecular test order management, workflow optimization, variant analysis, pathology sign-out, and HL7/XML reporting of discrete results. Discrete result reporting enables data integration with the EMR and other existing information systems in the laboratory and across the health system.

Sonde Health is a health technology company with a voice-enabled symptom detection and monitoring platform for chronic and mental health conditions. Our products are based on patented and proprietary, best-in-class technology developed by amazing people with advanced audio signal processing, speech science and machine learning backgrounds. We analyze over 4,000 vocal features that reflect changes in your voice caused by the changing physiology of your body due to symptoms of disease. Sonde's platform is designed with people's privacy in mind, and work on most smartphones people already own, preventing you from having to wear something new or add anything to your busy life.

Biotheranostics, Inc. has been acquired by Hologic. Hologic is an innovative medical technology company whose purpose is to enable healthier lives everywhere, every day. While we discover and develop groundbreaking products and services that benefit everyone, we are especially passionate about those that advance women’s health and well-being. This allows us to be a company that prospers, grows and empowers women to experience healthier lives.

GT Medical Technologies was founded by a dedicated team of brain tumor specialists to address unmet needs in brain tumor treatment. The company is committed to improving the lives of patients with brain tumors through innovative solutions that elevate the standard of care. GammaTile is an FDA-cleared, bioabsorbable collagen implant embedded with radiation seeds, designed for patients with operable brain tumors. By delivering radiation directly from within—placed into the surgical cavity at the time of tumor removal—GammaTile provides immediate, localized treatment. This approach targets remaining cancer cells when they are at their lowest levels to help prevent regrowth, while minimizing radiation exposure to healthy brain tissue.(1) Since its full market launch in the United States in March 2020, GammaTile has been adopted by more than 100 leading centers, underscoring its growing acceptance in both academic and community healthcare settings. For more information, visit gammatile.com. Reference: 1. Garcia MA et al. J Neurooncol. 166:203-212 (2024).

PreludeDx was founded to deliver actionable tools to manage early stage breast cancer. PreludeDx's first diagnostic test, DCISionRT is the result of over a decade of research and development focused on DCIS. PreludeDx began developing its DCIS test in 2009 after licensing technology from University of California, San Francisco. DCISionRT’s technology was designed from the beginning to address the critical question faced by patients with DCIS. What is my risk of recurrence and what treatment is appropriate?

Standard Molecular’s mission is to make clinical genomic testing routine. Personalized medicine, genetic testing, and cancer genomics present unique opportunities to clinicians in terms of diagnostic and therapeutic innovation. Standard Molecular, Inc. has developed Continuity GIS™, the first purpose-engineered Genomic Information System for molecular pathology. This tool was designed for molecular test order management, workflow optimization, variant analysis, pathology sign-out, and HL7/XML reporting of discrete results. Discrete result reporting enables data integration with the EMR and other existing information systems in the laboratory and across the health system.

Sonde Health is a health technology company with a voice-enabled symptom detection and monitoring platform for chronic and mental health conditions. Our products are based on patented and proprietary, best-in-class technology developed by amazing people with advanced audio signal processing, speech science and machine learning backgrounds. We analyze over 4,000 vocal features that reflect changes in your voice caused by the changing physiology of your body due to symptoms of disease. Sonde's platform is designed with people's privacy in mind, and work on most smartphones people already own, preventing you from having to wear something new or add anything to your busy life.

Magnolia Medical Technologies is on a Mission to ZERO®. Today, we offer healthcare institutions a solution to some of their biggest hidden problems – contamination leading to misdiagnosis of bloodstream infections, including sepsis, which can lead to unnecessary and prolonged antibiotic therapy, and false-positive CLABSIs. Tomorrow, we aspire to create a world free of in-vitro diagnostic errors where rapid, accurate test results improve the lives of patients and providers alike. We know that setting new standards of care is a journey enabled by purposeful innovation, partnerships, and perseverance. As the first step of our journey, we have successfully developed and proven our evidence-based technology platform, Steripath, which we’ve coupled with unparalleled support to change clinical practices and prevent unnecessary patient harm as well as system-wide costs associated with the misdiagnosis of sepsis. Our mission is further enabled by reducing false-positive CLABSIs and leveraging our extensive intellectual property portfolio – consisting of over 100 issued method, apparatus, and design patents and 70+ patent applications pending – to address other important sources of diagnostic error that are harmful to patients and costly to hospitals.